IB
Impact BioMedical Inc.
IBO · AMEX
$4.33 +5.35% (+$0.22)
1M -26.21%
Market Cap $35.5M
P/E Ratio 44.94x
Div. Yield -
ROE 13.70%
Bulios Fair Price
$2.21
49.0% downside
Current Price
$4.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, IBO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
16 /100
Expensive P/S 1,013.04x
P/B 3.29x
P/E 44.94x
Growth
0 /100
Declining Book val. growth 24.72%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 1,451.43%
Op. margin 14,562.90%
Gross margin 1,111.43%
Quality
58 /100
Average Asset turnover 0.00x
ROA 4.71%
ROIC 14.92%
Debt
46 /100
Moderate Current ratio 0.16x
Int. coverage -5.89x
Debt/Equity 0.00x
Stability
1 /100
Unstable EPS volatility 3,173.45%
Profitable years 0
Beta 2.76x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about IBO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Frank D. Heuszel
Employees
2
Headquarters
Houston